LOGC vs. IKNA, TSBX, ELUT, ATRA, TIL, DTIL, GNTA, ENTX, CDTX, and LENZ
Should you be buying LogicBio Therapeutics stock or one of its competitors? The main competitors of LogicBio Therapeutics include Ikena Oncology (IKNA), Turnstone Biologics (TSBX), Elutia (ELUT), Atara Biotherapeutics (ATRA), Instil Bio (TIL), Precision BioSciences (DTIL), Genenta Science (GNTA), Entera Bio (ENTX), Cidara Therapeutics (CDTX), and LENZ Therapeutics (LENZ).
Ikena Oncology (NASDAQ:IKNA) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.
Ikena Oncology has a net margin of 0.00% compared to Ikena Oncology's net margin of -131.05%. LogicBio Therapeutics' return on equity of -42.38% beat Ikena Oncology's return on equity.
In the previous week, Ikena Oncology had 14 more articles in the media than LogicBio Therapeutics. MarketBeat recorded 15 mentions for Ikena Oncology and 1 mentions for LogicBio Therapeutics. LogicBio Therapeutics' average media sentiment score of 0.80 beat Ikena Oncology's score of 0.00 indicating that Ikena Oncology is being referred to more favorably in the media.
Ikena Oncology presently has a consensus target price of $9.50, indicating a potential upside of 578.57%. Given LogicBio Therapeutics' higher probable upside, research analysts plainly believe Ikena Oncology is more favorable than LogicBio Therapeutics.
Ikena Oncology has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, LogicBio Therapeutics has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500.
LogicBio Therapeutics received 64 more outperform votes than Ikena Oncology when rated by MarketBeat users. Likewise, 64.08% of users gave LogicBio Therapeutics an outperform vote while only 60.00% of users gave Ikena Oncology an outperform vote.
Ikena Oncology has higher earnings, but lower revenue than LogicBio Therapeutics. Ikena Oncology is trading at a lower price-to-earnings ratio than LogicBio Therapeutics, indicating that it is currently the more affordable of the two stocks.
75.0% of Ikena Oncology shares are owned by institutional investors. Comparatively, 46.1% of LogicBio Therapeutics shares are owned by institutional investors. 6.0% of Ikena Oncology shares are owned by company insiders. Comparatively, 8.1% of LogicBio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Ikena Oncology beats LogicBio Therapeutics on 11 of the 17 factors compared between the two stocks.
Get LogicBio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LOGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LogicBio Therapeutics Competitors List
Related Companies and Tools
